- 专利标题： Treatment of CRTH2-mediated diseases and conditions
-
申请号： US12232444申请日： 2008-09-17
-
公开(公告)号： US08163931B2公开(公告)日： 2012-04-24
- 发明人: David Middlemiss , Mark Richard Ashton , Edward Andrew Boyd , Frederick Arthur Brookfield , Michael George Hunter , Mark Whittaker , Chris Palmer , Eric R. Pettipher
- 申请人： David Middlemiss , Mark Richard Ashton , Edward Andrew Boyd , Frederick Arthur Brookfield , Michael George Hunter , Mark Whittaker , Chris Palmer , Eric R. Pettipher
- 申请人地址： GB Abingdon, Oxon
- 专利权人： Oxagen Limited
- 当前专利权人： Oxagen Limited
- 当前专利权人地址： GB Abingdon, Oxon
- 代理机构： Sterne, Kessler, Goldstein & Fox P.L.L.C.
- 优先权： GB0324763.2 20031023
- 主分类号： C07D215/38
- IPC分类号： C07D215/38
摘要：
The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.
公开/授权文献
- US20090023788A1 Treatment of CRTH2-mediated diseases and conditions 公开/授权日：2009-01-22